Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose 5'-Azacitidine Maintenance Post-Transplant
NCT01995578Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2013
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), sponsored by Memorial Sloan Kettering Cancer Center. Started Dec 2013; status: completed.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01995578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01995578.